Hangzhou Diagens Biotechnology Co., Ltd. (02526.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 44.05B

MomentumView details →

1D Return

−1.76%

YTD Return

—

RSI (14)

53.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 44.05B

RSI (14)

53.3

MomentumView details →

1D Return

−1.76%

YTD Return

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Desh-B (02526.HK) completed the upgrade of its AI medical platform, transitioning from an AI device manufacturer to an AI platform service provider, leveraging its self-developed iMedImage foundation model and iMedLoop standardized AI production line.28d ago

Hangzhou Desheng Biotech reported interim results for the six months ended June 2026, with revenue of 108.7 million RMB, up 21.0% year-on-year, and a widened net loss of 55.88 million RMB.28d ago

Similar companies

Edwards Lifesciences CorporationEW 惠泰医疗688617.SH DexCom, Inc.DXCM Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series ABRKRP Boston Scientific CorporationBSX Koninklijke Philips N.V.PHG Find similar companies →

Latest newsMore news →

Desh-B (02526.HK) completed the upgrade of its AI medical platform, transitioning from an AI device manufacturer to an AI platform service provider, leveraging its self-developed iMedImage foundation model and iMedLoop standardized AI production line.28d ago Hangzhou Desheng Biotech reported interim results for the six months ended June 2026, with revenue of 108.7 million RMB, up 21.0% year-on-year, and a widened net loss of 55.88 million RMB.28d ago